Flerie

Flerie P/B

The P/B (Price-to-Book Ratio) of Flerie (FLERIE.ST) as of Nov 14, 2026 is 0.79. In the previous year, P/B (Price-to-Book Ratio) was 0.64 — a change of 24.32% (higher).

P/B

0.79

YoY

24.32%

Last updated:

P/B (Price-to-Book Ratio) of Flerie is 2025 0.79 . P/B (Price-to-Book Ratio) of Flerie was 2024 0.64 . It decreases by 24.32% higher compared to the previous year.

The Flerie P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
41.50 SEK
Jan 1, 2019
25.13 SEK
Jan 1, 2020
54.25 SEK
Jan 1, 2021
6.17 SEK
Jan 1, 2022
8.01 SEK
Jan 1, 2023
11.20 SEK
Jan 1, 2024
0.64 SEK
Jan 1, 2025
0.79 SEK
The Flerie P/B history
YEARP/BYoY
0.79+24.32%
0.64-94.31%
11.20+39.80%
8.01+29.97%
6.17-88.64%
54.25+115.91%
25.13-39.45%
41.50+62.42%
25.55+69.43%
15.08-82.87%
88.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Flerie Stock analysis

What does Flerie do? InDex Pharmaceuticals Holding AB develops drugs for inflammation and cancer, including cobitolimod for ulcerative colitis. The company offers a diagnostic kit called DiBiCol, which uses PCR to monitor seven biomarkers from colonic biopsies for ulcerative colitis or Crohn’s disease. InDex Pharmaceuticals AB and InDex Diagnostics AB are its subsidiaries, with SEB Venture Capital, Industrifonden, and NeoMed Management as shareholders. The firm focuses on pharmaceutical development and immuno-modulatory sequences (DIMS) for immunological diseases. The company generates revenue through the development and commercialization of cobitolimod and DIMS-based platforms. DiBiCol diagnostic kits are sold to healthcare providers for monitoring ulcerative colitis and Crohn’s disease. SEB Venture Capital, Industrifonden, and NeoMed Management are key investors supporting the company's research and development activities. InDex Pharmaceuticals Holding AB operates as a parent company for its subsidiaries in pharmaceutical and diagnostic fields. Flerie is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Flerie stock

P/B (Price-to-Book Ratio) of Flerie is 0.79 in 2025.

P/B (Price-to-Book Ratio) of Flerie changed from 0.64 to 0.79, representing a 24.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Flerie since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Flerie with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Flerie

All Key Metrics — Flerie